Omega Therapeutics IPO Presentation Deck

Investment Summary a ©2021 Omega Therapeutics, Inc Programmable mRNA therapeutics delivered by LNPs to specific cells and tissues It G ng DO Pioneering biology to precisely modulate gene expression by targeting IGDS without nucleic acid sequence changes Historically undruggable target cMYC as only the first of many Robust pre-clinical in-vivo data across multiple high-value uniquely addressable targets Over $200M raised with a diversified, world-class investor syndicate World class team focused on building an iconic company 31

View entire presentation